Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, with a high rate of recurrence even after complete surgical resection. The aim of this study was to investigate the impact of completion pancreatectomy (CP) on the clinical course of patients with recurrent PDAC in the remnant pancreas. Between January 2008 and December 2014, 194 patients underwent curative-intent surgical resection (initial pancreatectomy [IP]) for PDAC at our institution. The treatment and survival outcomes were evaluated according to the patterns of recurrence. Among 194 patients with IP, 127 patients (65.5%) developed recurrence. Of them, 11 patients (8.7%) developed recurrence in the remnant pancreas and were treated by CP. They showed a significantly longer median survival after the recurrence than the 28 patients who developed unresectable local recurrence and were treated by systemic chemotherapy (44 mo versus 11 mo, P = 0.014) or the 66 patients who developed distant metastasis and were treated by systemic chemotherapy (44 mo versus 13 mo, P = 0.024). Moreover, the median survival after CP was longer in the patients who received adjuvant chemotherapy after CP than in those who did not receive adjuvant chemotherapy (44 mo versus 14 mo, P = 0.002). This study demonstrated that PDAC patients with resectable local recurrence in the remnant pancreas, who were treated by CP, had better survival outcomes than those with other patterns of recurrence. CP combined with adjuvant chemotherapy appeared to yield greater survival benefit.